News

Tallie Z. Baram, MD, talks about how adding a measure of childhood unpredictability to ACEs screening may help pediatricians identify children at risk for mental health problems.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

The FDA granted priority review to efzimfotase alfa for HPP in patients aged 2 years and older; a decision is expected in the first half of 2027.

Adolescent VALIANT subgroup data show pegcetacoplan cut proteinuria 75% vs placebo, supporting its expanded pediatric kidney indication.

The FDA approved Fayuvi (rebisufligene etisparvovec-hopf), a one-time AAV9 gene therapy, as the first treatment for pediatric MPS IIIA (Sanfilippo syndrome type A).

Aquestive resubmitted its NDA for dibutepinephrine sublingual film Anaphylm, citing new human factors and PK data addressing the FDA's CRL.

Melissa Wallach, MD, FAAP, discusses what pediatricians should know about updated screening, supplementation, and treatment recommendations for iron deficiency.

A Bifidobacterium-based synbiotic was well tolerated and increased colonization of administered strains in infants and toddlers.

Children with atopic dermatitis have higher ADHD risk, particularly with early, severe disease and sleep disturbance, a review found.

Pediatricians can help teen athletes navigate sports supplements by prioritizing nutrition and identifying products to support, limit, or avoid.

Phase 3 CROSSING trial data show tezepelumab improved histologic remission and dysphagia versus placebo through week 52 in EoE.

FDA approved apitegromab-mstn (Isembyld) for SMA in patients 2 years and up, based on phase 3 data showing added motor gains with SMN2 therapy.

The FDA approved 40 mg and 50 mg twice-daily leniolisib (Joenja) for children ages 4 to 11 years weighing at least 27 kg with activated PI3Kδ syndrome.

This FAQ breaks down the AAP's newest COVID-19, RSV, and influenza recommendations for clinicians who want a quick refresher on what changed for the 2026-2027 season.

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Spot pediatric cancer red flags in everyday symptoms, avoid steroid missteps, act fast on emergencies, and guide survivors with smart follow-up.

XOCOVA gives pediatricians a new oral option to help prevent COVID-19 after exposure in adolescents aged 12 years and older.

Week 52 data from the reACHin trial show navepegritide stabilized foramen magnum stenosis and boosted growth in infants with achondroplasia.

Can you guess the diagnosis?

Phase 3 CANOPY-HCH-3 data show vosoritide significantly improved growth velocity, height, and arm span in children with hypochondroplasia.

A CDC-backed CHAMPS surveillance report across 7 countries finds 80% of child deaths were preventable, with gram-negative bacteria driving neonatal sepsis.

Semaglutide plus lifestyle changes moved 40.4% of children below the obesity threshold at 68 weeks in the phase 3 STEP Young trial.

Persephone's ARTEMIS trial found its Bifidobacterium-HMO synbiotic safe and effective at gut colonization in 114 infants and toddlers.

Can you guess the diagnosis?

Review some of the top stories from the Contemporary Pediatrics website over the last week, and catch up on anything you may have missed.

Get back-to-school pediatric guidance on vaccine updates, infection FAQs, screen time and mental health, nutrition changes, and standout cases to watch this year.

Abbott launches Similac 360 Total Care Made With Whole Milk, the first commercially sterile, ready-to-feed liquid formula made with whole milk sold in the US, priced near its powdered line.

A recap of the top FDA approvals, authorizations, and regulatory decisions affecting pediatric care during August 2026.